Eledon Pharmaceuticals, Inc. 8-K

What Happened
Eledon Pharmaceuticals, Inc. announced and furnished a press release on March 19, 2026 reporting its financial results for the quarter and fiscal year ended December 31, 2025. The press release is attached to the company’s Form 8‑K as Exhibit 99.1. The Form 8‑K (Item 2.02) was signed by David‑Alexandre C. Gros, M.D., Chief Executive Officer.

Key Details

• Form 8‑K filed and furnished on March 19, 2026 (Item 2.02: Results of Operations and Financial Condition).
• Results cover the quarter and year ended December 31, 2025.
• Press release announcing the results is attached as Exhibit 99.1 to the 8‑K.
• Filing executed by CEO David‑Alexandre C. Gros, M.D.

Why It Matters
This filing provides investors with Eledon’s latest quarterly and full‑year financial information, which can affect near‑term investor sentiment and trading. Retail investors should read the attached press release and any related SEC filings (e.g., Form 10‑K or 10‑Q) for the detailed figures on revenue, expenses, cash position, and management commentary to understand the company’s financial performance and outlook.